Cited 93 times in
Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김평환 | - |
dc.contributor.author | 손주혁 | - |
dc.contributor.author | 최정우 | - |
dc.date.accessioned | 2014-12-20T17:18:22Z | - |
dc.date.available | 2014-12-20T17:18:22Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0142-9612 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/94349 | - |
dc.description.abstract | PEGylation of adenovirus (Ad) increases plasma retention and reduces immunogenicity, but decreases the accessibility of virus particles to target cells. We tested whether PEGylated Ad conjugated to Herceptin (Ad-PEG-HER) can be used to treat Her2/neu-positive cells in vitro and in vivo to demonstrate the therapeutic feasibility of this Ad formulation. Ad-PEG-HER transduced Her2/neu-overexpressing cancer cells through a specific interaction between Herceptin and Her2/neu. Ad-PEG-HER treatment resulted in higher plasma retention and lower neutralizing antibody and IL-6 production than naked Ad. This formulation was extended to generate a Her2/neu-targeted, PEGylated oncolytic Ad (DWP418-PEG-HER). DWP418-PEG-HER specifically killed Her2/neu-positive cells and performed better than non-targeted and naked Ad in vivo. DWP418-PEG-HER showed a 10(10)-fold increase in the liver to tumor biodistribution compared with naked Ad. Immunohistochemical staining confirmed accumulation of Ad E1A in tumors. These data suggest that targeted gene therapy with the PEGylated Ad conjugated with Herceptin might shed a light on its therapeutic application for metastatic cancer in the future. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 2314~2326 | - |
dc.relation.isPartOf | BIOMATERIALS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenoviridae/drug effects | - |
dc.subject.MESH | Adenoviridae/metabolism* | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antibodies, Monoclonal/adverse effects* | - |
dc.subject.MESH | Antibodies, Monoclonal/pharmacokinetics | - |
dc.subject.MESH | Antibodies, Monoclonal/pharmacology* | - |
dc.subject.MESH | Antibodies, Monoclonal/toxicity | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized | - |
dc.subject.MESH | Antineoplastic Agents/pharmacology | - |
dc.subject.MESH | Cell Death/drug effects | - |
dc.subject.MESH | Cell Line, Tumor | - |
dc.subject.MESH | Drug Delivery Systems/methods* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunity, Humoral/drug effects | - |
dc.subject.MESH | Immunity, Innate/drug effects | - |
dc.subject.MESH | Injections, Intravenous | - |
dc.subject.MESH | Liver/drug effects | - |
dc.subject.MESH | Liver/pathology | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Oncolytic Viruses/drug effects | - |
dc.subject.MESH | Oncolytic Viruses/metabolism | - |
dc.subject.MESH | Polyethylene Glycols/chemistry* | - |
dc.subject.MESH | Receptor, ErbB-2/metabolism | - |
dc.subject.MESH | Tissue Distribution/drug effects | - |
dc.subject.MESH | Transduction, Genetic | - |
dc.subject.MESH | Trastuzumab | - |
dc.subject.MESH | Xenograft Model Antitumor Assays | - |
dc.title | Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Medical Research Center (임상의학연구센터) | - |
dc.contributor.googleauthor | Pyung-Hwan Kim | - |
dc.contributor.googleauthor | Joo-Hyuk Sohn | - |
dc.contributor.googleauthor | Joung-Woo Choi | - |
dc.contributor.googleauthor | Yukyung Jung | - |
dc.contributor.googleauthor | Sung Wan Kim | - |
dc.contributor.googleauthor | Seungjoo Haam | - |
dc.contributor.googleauthor | Chae-Ok Yun | - |
dc.identifier.doi | 10.1016/j.biomaterials.2010.10.031 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01088 | - |
dc.contributor.localId | A01995 | - |
dc.contributor.localId | A04179 | - |
dc.relation.journalcode | J00312 | - |
dc.identifier.eissn | 1878-5905 | - |
dc.identifier.pmid | 21227505 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0142961210013384 | - |
dc.subject.keyword | Cancer gene therapy | - |
dc.subject.keyword | Adenovirus | - |
dc.subject.keyword | Ad conjugated bioreducible polymer | - |
dc.subject.keyword | Hybrid vector | - |
dc.subject.keyword | Active targeting | - |
dc.contributor.alternativeName | Kim, Pyung Hwan | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.alternativeName | Choi, Joung Woo | - |
dc.contributor.affiliatedAuthor | Kim, Pyung Hwan | - |
dc.contributor.affiliatedAuthor | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | Choi, Joung Woo | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 32 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 2314 | - |
dc.citation.endPage | 2326 | - |
dc.identifier.bibliographicCitation | BIOMATERIALS, Vol.32(9) : 2314-2326, 2011 | - |
dc.identifier.rimsid | 27563 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.